NCT03009240View on ClinicalTrials.gov

Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 21, 2017

Primary Completion Date

March 30, 2026

Study Completion Date

March 30, 2026

Conditions
Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaTherapy-Related Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia
Interventions
DRUG

Decitabine

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Pevonedistat

Given IV

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER